{"id":"regadenoson-optison","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Flushing"},{"rate":"2-5%","effect":"Vomiting"},{"rate":"2-5%","effect":"Chest pain"},{"rate":"2-5%","effect":"Shortness of breath"},{"rate":"2-5%","effect":"Rapid heartbeat"},{"rate":"1-2%","effect":"Abnormal ECG"},{"rate":"1-2%","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL3989695","moleculeType":"Small molecule","molecularWeight":"408.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Regadenoson works by activating the adenosine A2A receptor, which increases coronary blood flow and myocardial perfusion. This results in increased oxygen delivery to the heart muscle, allowing for more accurate assessment of myocardial perfusion during stress testing.","oneSentence":"Regadenoson is a selective adenosine A2A receptor agonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:42.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Nuclear stress test for coronary artery disease"}]},"trialDetails":[{"nctId":"NCT01489176","phase":"PHASE3","title":"Regadenoson Real Time Perfusion Imaging Trial-Optison","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2012-07-31","conditions":"Coronary Artery Disease, Myocardial Perfusion Abnormalities","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lexiscan is the brand name for regadenoson."],"phase":"phase_3","status":"active","brandName":"Regadenoson; Optison","genericName":"Regadenoson; Optison","companyName":"University of Nebraska","companyId":"university-of-nebraska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Regadenoson is a selective adenosine A2A receptor agonist. Used for Nuclear stress test for coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}